Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31085Editorial articleПередовая статьяReview ArticlePHARMACOLOGICAL NEPHROPROTECTION IN CHRONIC KIDNEY DISEASE: CURRENT OPPORTUNITIES AND PERSPECTIVES (REVIEW OF FOREIGN LITERATURE)ФАРМАКОЛОГИЧЕСКАЯ НЕФРОПРОТЕКЦИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК: СОВРЕМЕННЫЕ ВОЗМОЖНОСТИ И ПЕРСПЕКТИВЫ (ОБЗОР ЗАРУБЕЖНОЙ ЛИТЕРАТУРЫ)NikolaevA YuНиколаевАлексей Юрьевич

Chair of Nephrology and Hemodialysis

д-р мед. наук, проф. каф. нефрологии и гемодиализа

nephrology@mail.ruRussian Medical Academy of Advanced Medical EducationРМАПО15062012846VOL 84, NO6 (2012)ТОМ 84, №6 (2012)768010042020Copyright ©; 2012, Consilium MedicumCopyright ©; 2012, ООО "Консилиум Медикум"2012Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31085

A brief literature review analyses pharmacoprotective strategy in most widespread forms of chronic kidney disease: metabolic syndrome, hypertensive angionephrosclerosis, diabetic and non-diabetic nephropathy. Nephroprotective properties of the blockers of rennin-angiotensin-aldosteron system and other antiadrenergic drugs, diuretics, hypolipidemic, antianemic and hypouricemic drugs, active metabolites of vitamin D, metphormine and glytasones are reviewed. The highest efficacy of combined pharmaconephroprotection is demonstrated.

В кратком обзоре литературы анализируется фармакопротективная стратегия при наиболее распространенных формах хронической болезни почек: метаболическом синдроме, гипертензивном ангионефросклерозе, диабетической и недиабетических нефропатиях. Рассматриваются нефропротективные свойства блокаторов ренин-ангиотензин-альдостероновой системы и других антиадренергических препаратов, диуретиков, гиполипидемических, антианемических и гипоурикемических препаратов, активных метаболитов витамина D, метформина и глитазонов. Показана наиболее высокая эффективность комбинированной фармаконефропротекции.

chronic kidney diseaseinhibitors of ACEblockers of angiotensin II receptorsblockers of calcium channelssalureticsspironolactonesstatinserythropoietinallopurinolparicalcitolхроническая болезнь почекингибиторы ангиотензинпревращающего ферментаблокаторы рецепторов ангиотензина IIблокаторы кальциевых каналовсалуретикиспиронолактоныстатиныэритропоэтиналлопуринолпарикальцитолDespres J. Potential contribution of metformin to the management of cardiovascular disease risk on patients with metabolic syndrome and type 2 diabetes. Diabet. Metab. 2003; 29: 653—661.Bakris G.L. Rosiglitazone reduces microalbuminuria and hypertension independently of glycemia in type 2 dibetes. J. Hypertens. 2006; 24: 2047—2055.Henry R. R., Lincoff A. M. Effect of the dual PPAR-alpha/gamma agonist aleglitazar on risk of cardiovascular disease in patients with type 2 diabetes. Lancet 2009; 374: 126—135.Dagenais G. R., Gerstein H. C., Holman R. Effect of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance: results of DREAM trial. Diabet. Care 2008; 31: 1007—1014.Makino H., Hakeda M., Babazono T. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: the INNOVATION study. J Hypertens. Res. 2008; 31: 657—664.Ruggenenti P., Perna A. REIN-2 study group. Blood pressure control for renoprotection in patients with non-diabetic CKD. Lancet 2005; 365: 939—946.Vogt L., de Zeeuw D., Woittiez A. J. Selective COX-2 inhibition reduces proteinuria in renal patients. Nephrol. Dial. Transplant. 2009; 24: 1182—1189.Marre M., Fernandez M., Garsia-Puig J. Value of natrilix SR in hypertensive type 2 diabetic patients with microalbuminuria. J. Hypertens. Res. 2002; 20 (Suppl. 4): 338—342.Mogensen C. E., Viberti G. C., Halimi S. Effect of low dose perindopril / indapamide on albuminuria in diabetes. Hypertension 2003; 41: 1063—1071.ADVANCE collaborate group. Effect of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus. Lancet 2007; 10: 140—167.Ruggenenti P. Bergamo Nephrologic Diabetic Complication study of the combination trandolapril with verapamil. N. Engl. J. Med. 2004; 351: 1941—1951.Alleman Y., Fraile B., Lambert M. Efficacy of the combination of amlodipine and valsartan in patients uncontrolled with monotherapy: Ex-FAST study. J. Clin. Hypertens. (Greenwich) 2008; 10: 185—194.Tunon J., Blanco-Colio L. M., Martin-Ventura J. L. Intensive treatment with statins and progression of cardiovascular disease. Nephrol. Dial. Transplant. 2004; 19: 2696—2699.Tonelly M., Moye L., Sacks F. M. Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal failure (CARE). Ann. Intern. Med. 2003; 138: 98—104.Keech A., Simes R. J., Barter P. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study). Lancet 2005; 366: 1849—1861.Zhou Y., Kong X., Zhao P. PPAR-alpha is renoprotective in doxorubicin-induced glomerular injury. Kidney Int. 2011; 79: 1302—1311.Gatto A. L., Saag K. G. Management of hyperuricemia and gout in CKD. Am. J. Kidney Dis. 2008; 52: 994—1009.Contras G., Green T. AASK study group. Blood pressure control and kidney disease. Hypertension 2005; 46: 44—50.Hair P. I., Scott L. J., Perry C. M.Fixed-dose combination lercanidipine/enalapril. Drugs 2007; 67: 95—106.Mogensen C. E., Viberti G. C. Dual blockade of RAS in patients with hypertension, microalbuminuria and NIDDM: the candesartan and lisinopril microalbuminuria study — CALM. Brit. Med. J. 2000; 321: 1440—1444.Benson S. C., Pershadsingh H. A., Ho C. I. Identification of telmisartan as a unique AII receptor antagonist with selective PPAR-gamma-modulating activity. Hypertension 2004; 43: 993—1002.Zhang Z. et al. Combination therapy with AT1 blockers and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin release. Proc. Natl. Acad. Sci. USA 2008; 41: 15896—15901.Asmus H.-G., Braun J., Krause R. Sevelamer and Ca carbonate effects on cardiovascular calcification and bone density. Nephrol. Dial. Transplant. 2005; 20: 1653—1661.Olivera R. B., Cancela A. L., Graciolli F. G. Early control of PTH and FGF 23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin. J. Am. Soc. Nephrol. 2010; 5: 286—291.Schmieder R.E., Philipp T., Guerediaga J. Long-term antihypertensive efficacy and safety of the direct renin inhibitor aliskiren a 12 month randomized traial with hydrochlorthiazide. Circulation 2009; 119: 417—425.Rahman M., Pressel S., Davis B. R. Renal outcomes in high-risk hypertensive patients treated with ACEI or calcium channel blocker versus diuretics: a report of ALLHAT trial. Arch. Intern. Med. 2005; 165: 936—946.Julius S., Kjeldsen S. E., Weber M. Outcomes in hypertensive patients at high cardiovascular risk treated with regimen based on valsartan or amlodipine: the VALUE trial. Lancet 2004; 363: 2022—2031.Danlof B., Sever P. S. ASCOT investigation: prevention of cardiovascular events with amlodopine adding perindopril. Lancet 2005; 366: 895—906.Lopez B., Gonzalez A., Hermida N. Myocardial fibrosis in CKD: potential benefits of torasemide. Kidney Int. 2008; 74 (Suppl. 111): S19—S23.Pitt B., Remme W. J., Zannad F. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N. Engl. J. Med. 2003; 348: 1309—1321.Laville M. Anaemia correction in diabetes trial. New strategies in anaemia management: ACORD. Acta Diabetol. 2004; 41 (Suppl. 1): S18—S22.Fishbane S. Erythropoiesis-stimulating agent treatment with full anemias correction: a new perspective. Kidney Int. 2009; 75: 358—365.McGavin J., Keating G. Bisoprolol. A review of its use in chronic heart failure. Drugs 2002; 62: 2677—2696.Cice G., Ferrara L., Andrea A. Carvedilol increases two-year survival in dialysis patients with cardiomyopathy. J. Am. Coll. Cardiol. 2003; 41: 1438—1444.